Spots Global Cancer Trial Database for e7389
Every month we try and update this database with for e7389 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | NCT00413192 | Soft Tissue Sar... | E7389 | 18 Years - | Eisai Inc. | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Study of E7389 in Patients With Advanced Solid Tumors | NCT00069264 | Advanced Solid ... | E7389 | 18 Years - | Eisai Inc. | |
| An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function | NCT01418677 | Unspecified Adu... | E7389 E7389 E7389 | 18 Years - | Eisai Inc. | |
| Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System | NCT00706095 | Cancer | E7389 E7389 E7389 | 18 Years - | Eisai Inc. | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine | NCT00246090 | Breast Cancer | E7389 | 18 Years - | Eisai Inc. | |
| A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | NCT03437083 | Locally Advance... | Eribulin mesyla... | - | Eisai Inc. | |
| E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma | NCT00413192 | Soft Tissue Sar... | E7389 | 18 Years - | Eisai Inc. | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | NCT01126749 | Bladder Cancer | Gemcitabine E7389 Cisplatin | 18 Years - | Eisai Inc. | |
| A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants | NCT03437083 | Locally Advance... | Eribulin mesyla... | - | Eisai Inc. | |
| A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas | NCT03058406 | Sarcoma, Soft T... | Eribulin mesyla... | - | Eisai Inc. | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00388726 | Breast Cancer | E7389 Physician's Cho... | 18 Years - | Eisai Inc. | |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | NCT00278993 | Prostate Cancer | E7389 | 18 Years - | Eisai Inc. | |
| Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System | NCT00706095 | Cancer | E7389 E7389 E7389 | 18 Years - | Eisai Inc. | |
| Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | NCT01593020 | Breast Cancer | Paclitaxel Eribulin 5-Fluorouracil Epirubicin Cyclophosphamid... Doxorubicin | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy | NCT00278993 | Prostate Cancer | E7389 | 18 Years - | Eisai Inc. | |
| A Study of E7389 in Advanced/Metastatic Breast Cancer Patients | NCT00097721 | Breast Neoplasm... | E7389 | 18 Years - | Eisai Inc. | |
| Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors | NCT00069277 | Cancer | E7389 | 18 Years - | Eisai Inc. | |
| Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | NCT01126749 | Bladder Cancer | Gemcitabine E7389 Cisplatin | 18 Years - | Eisai Inc. | |
| To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors | NCT03002493 | Tumor | Eribulin mesyla... Eribulin mesyla... Rifampicin | 18 Years - | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
